Title: Cardiovascular health in early pregnancy and circulating placental biomarkers

Andrea C. Kozai, PhD[1], Bethany Barone Gibbs, PhD[2], Samuel Parry, MD[3], Sadiya S. Khan, MD, MSc[4], William Grobman, MD, MBA[5], Lisa D. Levine, MD, MSCE[3], Rebecca McNeil, PhD[6], David M. Haas, MD, MS[7], Jessica L. Pippen, MD[8], Robert M. Silver, MD[9], Judith H. Chung, MD, PhD[10], Janet M. Catov, PhD[1]

[1]Department of Epidemiology, University of Pittsburgh School of Public Health
[2]Department of Epidemiology and Biostatistics, West Virginia University School of Public Health
[3]Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine
[4]Department of Medicine Northwestern University Feinberg School of Medicine
[5]Department of Obstetrics and Gynecology, Brown University School of Medicine
[6]Research Triangle International
[7]Department of Obstetrics & Gynecology Indiana University School of Medicine
[8]The MetroHealth System, Case Western Reserve University
[9]Department of Obstetrics and Gynecology, University of Utah
[10]Department of Obstetrics and Gynecology, University of California, Irvine

Corresponding author:
    Andrea C. Kozai
    130 N. Bellefield Ave
    Pittsburgh, PA 15213
    andrea.kozai@pitt.edu

Abstract – 250 of 250 words

Background

Maternal cardiovascular and placental health are related to pregnancy outcomes, yet how cardiovascular health (CVH) in early pregnancy affects placentation is not well characterized. Our objective was to estimate associations between CVH and concentrations of placental proteins. We hypothesized that more favorable CVH metrics would be associated with more favorable circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble FMS-like tyrosine kinase 1 (sFlt-1), and soluble endoglin (sEng) in the 1st and 2nd trimesters.

Methods

Participants from the nuMoM2b prospective cohort with valid biomarker measures were included (n=2188). Maternal CVH was defined using the American Heart Association's Life's Essential 8 composite score, averaging six components measured in the 1st trimester: body mass index (BMI), blood pressure, physical activity, diet, sleep duration, and smoking. Individual component scores were also evaluated. Linear regression associated scores with 1st and 2nd trimester circulating placental biomarkers.

Results and Conclusions

Higher (more favorable) composite CVH scores were associated with higher PAPP-A (favorable) in both trimesters. In contrast, higher CVH scores were associated with lower

VEGF, higher sFlt-1, and higher sEng in the 1st trimester (adverse). Healthier BMI scores demonstrated similar associations as those found with composite CVH. Greater physical activity was associated with more favorable 1st trimester profiles (higher VEGF and lower sFlt-1), but lower 2nd trimester PAPP-A. Composite CVH, potentially driven by BMI and physical activity components, may be an important factor relating to circulating concentrations of placental biomarkers in the first half of pregnancy.

Keywords: nuMoM2b; placental growth and development; angiogenic balance; maternal fetal health; Life's Essential 8; health behaviors

Non-standard Abbreviations and Acronyms

APO – Adverse pregnancy outcomes

BMI – Body mass index

CVH – Cardiovascular health

HEI – Healthy Eating Index

METs – Metabolic equivalents of the task

nuMoM2b – Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be

PAPP-A – Pregnancy-associated plasma protein A

PlGF – Placental growth factor

PTB – Preterm birth

sEng – Soluble endoglin

sFlt-1 – Soluble FMS-like tyrosine kinase 1

SGA – Small for gestational age

VEGF – Vascular endothelial growth factor

Introduction

Pregnancy is a cardiovascular stress test.[1–3] Many adverse pregnancy outcomes (APOs) are associated with poor placental implantation and development[4–7], but the mechanisms connecting maternal cardiovascular health (CVH), poor placental development, and APOs are still being elucidated.[8] Risk factors for APOs are similar to those for cardiovascular disease, indicating shared pathophysiology may exist.[2] Evidence is needed to identify those at increased risk who may benefit from early intervention, particularly among those with no prior pregnancy history.

The placenta is a dynamic organ that undergoes phases of development depending on the gestational age of the pregnancy.[9,10] Placental biomarkers are shed into maternal circulation across gestation, with elevated or reduced concentrations of specific biomarkers in pregnant individuals who ultimately develop APOs.[11–14] Biomarkers of interest include pregnancy-associated plasma protein A (PAPP-A), vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble FMS-like tyrosine kinase 1 (sFlt-1), and soluble endoglin (sEng). Limited evidence shows that components of CVH in pregnancy may be associated with placental biomarkers[15,16], and further data are needed to understand which components may be most closely related to circulating concentrations in early and mid-pregnancy.

The American Heart Association has set scoring standards for key components of "ideal" CVH, including health behaviors (physical activity, diet, smoking, and sleep duration) and health factors (blood pressure, glucose, lipids, and body mass index [BMI]).[17,18] Higher (more favorable) CVH scores in pregnancy are associated with lower risk

of adverse outcomes.[19] While each individual CVH component is associated with pregnancy outcomes[15,20–25], data associating these components with placental biomarkers are scant.[15,16] This limits our understanding of the mechanisms involved in the relationship between CVH and APOs.

The purpose of this study was to examine whether CVH parameters measured in the 1st trimester were associated with circulating maternal concentrations of placental biomarkers in the 1st or 2nd trimesters of pregnancy. We hypothesized that more ideal composite and individual component CVH scores measured in the 1st trimester would be associated with more favorable biomarker concentrations including higher PAPP-A, VEGF, and PlGF, and lower sFlt-1 and sEng in the 1st and 2nd trimesters.

Methods

Sample

A subset of participants from the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers to Be (nuMoM2b) prospective cohort comprised the sample for this study. Full methods for the cohort have been published previously.[26] Briefly, nulliparous participants pregnant with a singleton gestation were recruited in early pregnancy (6^0-13^6 weeks' gestation) and assessed three times throughout pregnancy (baseline, 16^0-21^6 weeks' gestation and 22^0-29^6 weeks' gestation) and at delivery at eight clinical sites in the United States. Ethical approval was obtained at each clinical site and participants provided informed consent prior to data collection. Biomarker assays were conducted on a subset of 1st and 2nd trimester maternal serum samples drawing from individuals who delivered after 20 weeks of gestation and provided sufficient serum.[11] All cases of APO (preterm

birth, preeclampsia, stillbirth, and/or small-for-gestational-age birth), as well as a random

sample of 12% of the remaining individuals with uncomplicated, term deliveries, were

included in the subset.[11]

Cardiovascular Health Score

Each component of the CVH score was assessed in the 1st trimester at the baseline

visit and assigned a score on a scale of 0-100 according to the Life's Essential 8 scoring

algorithm, in which higher scores indicate more favorable health.[18] The full scoring

algorithm can be found in **Table S1**.

Physical activity was assessed via a self-report questionnaire, in which participants

identified frequency, duration, and type of activities over the past four weeks. Average

minutes per week of moderate (3.0-5.9 metabolic equivalents of task [METs]) and vigorous

($\geq$6.0 METs) leisure time physical activity were calculated based on corresponding MET

values from the Compendium of Physical Activities[27], and weekly duration of physical

activity as it pertains to U.S. federal guidelines was calculated as minutes of moderate plus

2 x minutes of vigorous activity.[28] CVH scores ranged from 0 (no weekly physical activity) to

100 ($\geq$150 minutes/week) with intermediate scores for values between 0-150

minutes/week. Physical activity was additionally categorized into none (no weekly physical

activity), insufficient (1-149 minutes/week), sufficient (150-299 minutes/week), and high

(300+ minutes/week).

The Healthy Eating Index (HEI) score was used to assess diet quality and was

determined using a modified Block Food Frequency Questionnaire[29,30] with reference to the

three-month period immediately preceding conception. CVH scores were based on

percentiles of HEI scores in the full nuMoM2b sample; for example, 0 points corresponded to HEI <25th percentile, while 100 points corresponded to HEI ≥95th percentile.

Self-reported weekday and weekend hours of nightly sleep were used to determine sleep duration. Weighted averages were calculated to account for differences between weekday and weekend sleep duration, and CVH scores were assigned based on the U-shaped association between sleep duration and cardiovascular health (i.e., both low and high sleep durations are adverse).

Participants self-reported combustible tobacco use and exposure to secondhand smoke in the home. CVH scoring for smoking was adapted from the standard scoring algorithm (see **Table S1**). A score of 0 indicated current smoking during pregnancy, while a score of 100 indicated never smoking tobacco; intermediate scores were assigned for former smokers. 20 points were subtracted in cases of exposure to secondhand smoke in the home for all except current smokers.

Blood pressure, height, and weight were measured in person by research personnel using standardized techniques. Body mass index (BMI, kg/m^2) was calculated from height and weight. Blood draws were obtained in a non-fasted state, so the lipid and glucose components of the composite CVH score were excluded from this analysis. The composite CVH score was derived by averaging the scores of the six available components: physical activity, diet, sleep, smoking, blood pressure, and BMI. Composite CVH scores were categorized into high CVH (80-100 points), moderate CVH (50-79 points), and poor CVH (<50 points) for analysis.[18]

Placental blood analytes

Full methodology of the biomarker assays have been published previously[11]; in brief, blood serum samples collected at the study visits in the 1st and 2nd trimester were stored at -70° C prior to being assayed. Biomarker concentrations were measured using enzyme-linked immunosorbent assay (sEng), electrochemiluminescence assay (VEGF and sFlt-1), or lanthanide-based time resolved fluorometry (PlGF and PAPP-A). Concentrations below the limits of detection were assigned values equal to half the lower limit, while those above the upper limit were assigned a value equal to the upper limit.

Covariates

Demographic information including age, race/ethnicity, educational attainment, income, and health insurance status were self-reported via questionnaire at the baseline visit. At the second visit, participants completed the Krieger Discrimination Scale[31] to assess experiences with racial discrimination and the Connor-Davidson Resilience Scale[32] to assess resilience.

Statistical Analyses

Distributions of placental blood biomarkers were examined for normality and log-transformed if appropriate. Descriptive characteristics were compared among composite CVH categories using Chi-square tests for categorical variables and analysis of variance for continuous variables.

Associations between a) composite CVH score categories and b) individual component scores with each placental blood biomarker were examined using linear regression. First, a cross-sectional analysis examined the association between 1st trimester CVH metrics and 1st trimester biomarker concentrations. Next, a longitudinal analysis

examined the association between 1st trimester CVH metrics and 2nd trimester biomarker concentrations. Scatterplot visualizations of the associations between physical activity scores and the biomarkers suggested a nonlinear association, so physical activity was analyzed categorically (none, 0 minutes/week; insufficient, 1-149 minutes/week; sufficient, 150-299 minutes/week; and high, ≥300 minutes/week). BMI, blood pressure, diet, sleep duration, and smoking were analyzed as continuous CVH component scores.

Sampling weights were added to all analyses to account for the oversampling of APOs in the placental analyte subsample. All cases of APOs with sufficient serum were assayed (n=1,349); therefore, a sampling weight of 1 was applied to each APO case. Of the remaining participants with full-term uncomplicated pregnancy outcomes and sufficient serum, 11.8% were selected at random for assays (n=839). Thus, a sample weight of 8.48 (equal to 1/0.118) was applied to all non-APO controls. This method is similar to those used in nationally-representative cohorts such as the National Health and Nutrition Examination Survey[33] and other prospective pregnancy cohort studies.[34]

All linear regression models were adjusted for gestational age at the blood draw, and longitudinal analyses were additionally adjusted for 1st trimester biomarker concentrations. These minimally adjusted models were further adjusted for demographic characteristics, BMI (blood pressure and health behavior component analyses only), perceived racial discrimination, and resilience in a backwards stepwise approach in which covariate associations with a p-value <0.2 were retained in the final model (See **Table S2** for covariates in each model). All analyses were conducted in Stata SE version 18

(StataCorp, College Station, TX) and significant associations were accepted at p<0.01 to account for multiple comparisons while limiting Type II error.

Results

Participants

Of the 10,038 nuMoM2b participants, 2,188 were included in this analysis (**Figure 1**). Mean weighted baseline age of the included sample was 26.9±5.8 years and mean weighted BMI was 26.9±6.8 kg/m^2. Participants included in this analysis had similar weighted rates of APOs but had significantly lower weighted BMI and were more likely to report non-Hispanic White race, lower perceived racial discrimination, and use of commercial insurance than the full cohort (**Table S3**).

Composite CVH Scores

The mean weighted composite CVH score in the 1st trimester for this sample was 71.1 ± 15.4 points. Thirty percent of participants achieved high CVH (≥80 points), 56% had moderate CVH (50-79 points), and 14% had poor CVH (<50 points, **Table 1**).[18] Participants with high CVH were more likely to be older, non-Hispanic White, with a lower BMI and more education, higher income, or commercial insurance than those with moderate or poor CVH. Furthermore, the rate of APO was significantly lower in the high CVH group. Absolute concentrations of each placental biomarker by CVH group in each trimester can be found in **Table S4**.

Circulating PAPP-A

High CVH was associated with a higher (more favorable) adjusted 1st trimester circulating PAPP-A concentration (2.98 log mU/mL, 95% CI [2.93, 3.04]) than both moderate CVH (2.88 log mU/mL, 95% CI [2.82, 2.92], p=0.004) and poor CVH (2.61 log mU/mL, 95% CI [2.49, 2.72], p<0.001). Results were similar when evaluated in longitudinal analysis estimating the association of 1st trimester composite CVH with 2nd trimester PAPP-A concentrations (3.94 log mU/mL, 95% CI [3.91, 3.96] for those with high CVH versus 3.82 log mU/ml, 95% CI [3.75, 3.89] for those with poor CVH, p=0.002).

Circulating VEGF, PlGF, sFlt-1, and sEng

The high vs. poor CVH group had lower adjusted circulating VEGF in the 1st trimester (-0.13 log pg/mL, 95% CI [-0.18, -0.08] versus 0.10 log pg/mL, 95% CI [-0.05, 0.24], p=0.006) and higher circulating sFlt-1 concentrations in the 1st trimester (2.97 log pg/mL, 95% CI [2.95, 2.99] versus 2.90 log pg/mL, 95% CI [2.86, 2.94], p=0.004; **Table 2**). Furthermore, high CVH was associated with higher adjusted circulating 1st trimester sEng than poor CVH (6.81 ng/mL, 95% CI [6.61, 7.00] versus 5.79 ng/mL, 95% CI [5.43, 6.15], p<0.001). No longitudinal associations were detected between composite CVH and 2nd trimester angiogenic biomarker concentrations.

Individual Component Scores

Circulating PAPP-A

Higher (more favorable) component scores for BMI and blood pressure were associated with higher 1st trimester PAPP-A concentrations in minimally-adjusted models (**Table 3**, p<0.001 for each), but only BMI remained significantly associated following

covariate adjustment. Similar results were detected when BMI was evaluated longitudinally with PAPP-A concentrations in the 2nd trimester. No significant associations were found between component scores for any of the health behaviors and 1st trimester PAPP-A concentrations.

Participants reporting no weekly 1st trimester physical activity had significantly higher 2nd trimester PAPP-A than those reporting insufficient, sufficient, or high physical activity (**Figure 2a**, $p < 0.001$ for all). While 1st trimester physical activity was associated with lower 2nd trimester concentrations of PAPP-A, a significantly lower proportion of those reporting sufficient weekly physical activity had an APO compared to those reporting no weekly physical activity (**Figure 2b**, $p < 0.01$).

Circulating VEGF, PlGF, sFlt-1, and sEng

Higher (more favorable) component scores for BMI and blood pressure were significantly associated with lower 1st trimester concentrations of VEGF, higher 1st trimester concentrations of sFlt-1, and higher 1st trimester concentrations of sEng; only the associations with BMI remained significant following covariate adjustment (**Table 3**). In longitudinal analyses, a more favorable 1st trimester BMI score was associated with a higher 2nd trimester concentration of PlGF, which was robust to covariate adjustment.

Engaging in physical activity was associated with a higher 1st trimester VEGF concentration (**Figure 2c**, $p < 0.001$ for insufficient and high physical activity compared to none). High physical activity was associated with lower 1st trimester sFlt-1 concentration versus no weekly physical activity (**Figure 2d,** $p = 0.003$). These associations with physical activity were robust to covariate adjustment. No associations with blood pressure,

smoking, diet, or sleep scores were detected following covariate adjustment (**Tables 3 & S5**).

Discussion

Our findings demonstrate the complex interplay between maternal CVH and placental biomarkers in nulliparous pregnant participants, with associations in both expected and unexpected directions (**Figure 3**). BMI emerged as the only component that was significantly associated with each circulating biomarker (PAPP-A, VEGF, sFlt-1, and sEng in the 1st trimester, and PAPP-A and PlGF in the 2nd trimester), though associations with 1st trimester angiogenic biomarkers were in the opposite direction as hypothesized. Physical activity was the only health behavior that was associated with biomarkers independent of BMI, with expected directions of associations with 1st trimester angiogenic biomarkers and an unexpected direction with 2nd trimester PAPP-A. These results suggest that BMI is an important factor relating to circulating placental biomarkers in early and mid-pregnancy, and physical activity may be the predominant health behavior relating to placental biomarkers during this first half of pregnancy.

Circulating PAPP-A

PAPP-A concentrations increase across gestation in normal pregnancy[35,36] and display dysregulated trajectories in cases of APOs.[37] In preeclampsia, 1st trimester PAPP-A is lower than normal, then increases exponentially in the 3rd trimester to levels above normal.[14] We found that those with favorable 1st trimester CVH had higher 1st trimester

circulating PAPP-A than those with moderate or poor CVH. As higher concentrations of this

biomarker in early gestation are associated with better pregnancy outcomes, this finding

suggests that higher early-pregnancy CVH may be related to more robust placentation and

concomitant higher concentrations of PAPP-A. Furthermore, the strong association

between more favorable BMI component scores and higher PAPP-A suggests that a healthy

BMI, in particular, may be important for healthy placentation.

In contrast, the association between greater 1st trimester physical activity and lower

2nd trimester concentrations of PAPP-A suggests that physical activity in early pregnancy

may be related to less robust placental growth and development by mid-pregnancy. This

finding is in the opposite direction from our hypothesis, yet it is important to note that it did

not appear to be pathologic – participants who self-reported at least 150 minutes/week of

1st trimester physical activity had a significantly lower rate of APOs than those who self-

reported no weekly physical activity. We speculate this finding may be due to the timing of

the PAPP-A measurement. In the 2nd trimester, PAPP-A concentrations are similar between

individuals who ultimately develop healthy and adverse pregnancy outcomes; low PAPP-A

is adverse in the 1st trimester, but high PAPP-A is adverse in the 3rd trimester.[12,14] It is

possible that the lower 2nd trimester PAPP-A concentrations we found in those engaging in

physical activity may be indicative of physical activity eliciting a protective effect against

higher late-pregnancy concentrations, but this warrants further study.

Circulating VEGF, PlGF, sFlt-1, and sEng

We found that healthier 1st trimester composite CVH scores and BMI component

scores were associated with lower concentrations of VEGF, while more self-reported 1st

trimester physical activity was associated with higher 1st trimester VEGF. Outside of pregnancy, higher VEGF concentrations are associated with obesity and metabolic syndrome[38–40] which may be due to the angiogenic burden to support adipose tissue. However, exercise is also associated with higher VEGF expression and circulating concentrations outside pregnancy, though from a physiological perspective of supporting oxygen delivery to the musculature.[40–42] Limited pregnancy literature supports both these associations, with higher placental VEGF expression in those with gestational diabetes and high gestational weight gain[43,44] as well as in active versus inactive pregnant individuals.[45] It is important to note that these angiogenic biomarkers are produced by several tissue types in addition to the placenta, and circulating concentrations cannot discriminate between placental versus maternal tissue origins. It is possible that the associations we detected are indicative of both placental and maternal tissue contributions to circulating VEGF concentrations.

Similarly, we found that healthier 1st trimester composite CVH scores and BMI component scores were associated with higher concentrations of sEng, opposite to our hypothesis. Higher concentrations of sEng in early- and mid-pregnancy are associated with higher risk for preeclampsia.[13,46,47] However, maternal obesity has been linked with lower circulating concentrations of sEng.[48] We also found healthier BMI component scores were associated with higher 1st trimester sFlt-1. This finding supports prior literature demonstrating that maternal obesity is associated with lower sFlt-1 in early pregnancy, which may be related to greater plasma volume or higher concentrations of sFlt-1 degrading heparin sulfate proteoglycans.[48–51] Healthier BMI scores were also associated

with higher 2nd trimester PlGF concentrations in our study. Prior literature has found similar results, with lower mid-pregnancy PlGF concentrations found in those with higher BMI.[48,51] It is possible that a healthy early-pregnancy BMI is related to a more robust placenta that is capable of synthesizing sufficient PlGF by mid-pregnancy.

Finally, we found that more self-reported 1st trimester physical activity was associated with lower sFlt-1 concentrations in the 1st trimester. This confirms the findings of a prior study in the same cohort that only examined physical activity, and found significantly lower sFlt-1 concentrations in those above versus below 150 min/week physical activity.[15] Our results expand on this finding, as we demonstrated that the lowest concentration of sFlt-1 was seen in those reporting ≥300 min/week physical activity and that those reporting 150-299 min/week were not significantly different from those reporting no weekly physical activity. This suggests that physical activity may indeed be a potential mechanism to reduce the antiangiogenic sFlt-1 concentration in early pregnancy[15], but it may require high volumes of physical activity to reach this target.

Strengths and Limitations

This study is bolstered by several strengths. We used a diverse national cohort of nulliparous individuals, in which robust data were collected across pregnancy. This allowed us to examine both cross-sectional and longitudinal associations between CVH and placental biomarkers in the 1st and 2nd trimesters, which is of particular importance given the dynamic nature of placental development throughout pregnancy.[52,53]

Certain limitations are acknowledged. The sample for this analysis was comprised of all cases of APO and a random sample of remaining participants with uncomplicated

full-term pregnancies from the parent study. While we used sampling weights to account

for this, some differences remained between our weighted sample and the full cohort.

Multiple comparisons may have led to a Type I error, though we used an *a priori* cutoff of

p<0.01 to mitigate this risk. By only analyzing those whose pregnancies continued beyond

20 weeks of gestation our results may be impacted by survivorship bias. Health behaviors

were all self-reported, although participants were not aware of biomarker concentrations

at the time of behavior recall so non-random bias should be minimal. The diet assessment

referenced the 3 months prior to conception and may not have been representative of 1st

trimester dietary intake. We did not have fasting blood glucose or lipids and so were not

able to examine the full spectrum of CVH components, and we did not have placental

histology data to directly examine morphology outcomes. Finally, we did not adjust for

medications; while it is possible that aspirin therapy could have impacted our results, prior

analysis in this cohort found less than 2% of participants reported aspirin use during their

pregnancy and a recent clinical trial found no effect of aspirin therapy on circulating

concentrations of PAPP-A and PlGF.[54,55]

Conclusions

　　Maternal CVH in the 1st trimester of pregnancy is associated with circulating

concentrations of placental biomarkers. While many of our findings were in the

hypothesized direction wherein a healthier CVH score was associated with healthier

circulating concentrations, others were in the opposite direction. Our findings suggest that

maternal BMI may have a complex relationship with these biomarkers. In some cases

(PAPP-A in both trimesters and 2nd trimester PlGF), a healthier BMI was indicative of more

robust placentation. In contrast, a less favorable BMI was associated with a more pro-angiogenic balance of 1st trimester VEGF, sFlt-1, and sEng. We cautiously interpret this finding to suggest that maternal systemic factors such as the higher angiogenic demand of adipose tissue in the setting of obesity may play a larger role than placental factors in angiogenic protein concentrations in early pregnancy. Finally, of the five remaining CVH components (blood pressure, physical activity, diet, sleep duration, and smoking), only physical activity was independently associated with circulating biomarker concentrations when accounting for BMI. Future investigations of biomarker concentrations in early pregnancy should include BMI as a covariate, and physical activity may be a target for interventions in this population.

Sources of Funding: The nuMoM2b project was supported by grant funding from the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD): U10 HD063036; U10 HD063072; U10 HD063047; U10 HD063037; U10 HD063041; U10 HD063020; U10 HD063046; U10 HD063048; and U10 HD063053. In addition, support was provided by Clinical and Translational Science Institutes: UL1TR001108 and UL1TR000153. The nuMoM2b Heart Health Study was supported by cooperative agreement funding from the National Heart, Lung, and Blood Institute and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development: U10-HL119991; U10-HL119989; U10-HL120034; U10-HL119990; U10-HL120006; U10-HL119992; U10-HL120019; U10-HL119993; U10-HL120018, and U01HL145358; with supplemental support to NHLBI U10-HL119991 from the Office of Research on Women's

Health and the Office of Disease Prevention and to NHLBI U01HL145358 from the Office of Research on Women's Health; and the National Center for Advancing Translational Sciences through UL-1-TR000124, UL-1-TR000153, UL-1-TR000439, and UL-1-TR001108; and the Barbra Streisand Women's Cardiovascular Research and Education Program, and the Erika J. Glazer Women's Heart Research Initiative, Cedars-Sinai Medical Center, Los Angeles. The Sedentary Behavior and Cardiovascular Health in Young Women ancillary study is supported by NHLBI R01HL158652. ACK is supported under NHLBI T32HL083825.

References

1. Brislane Á, Steinback CD, Davenport MH. The 9-Month Stress Test: Pregnancy and Exercise—Similarities and Interactions. *Canadian Journal of Cardiology*. 2021;37(12):2014-2025. doi:10.1016/j.cjca.2021.09.003

2. Khan SS, Cameron NA, Lindley KJ. Pregnancy as an Early Cardiovascular Moment: Peripartum Cardiovascular Health. *Circulation Research*. 2023;132(12):1584-1606. doi:10.1161/CIRCRESAHA.123.322001

3. Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes. *Journal of the American College of Cardiology*. 2019;73(16):2106-2116. doi:10.1016/j.jacc.2018.12.092

4. Parks WT, Catov JM. The Placenta as a Window to Maternal Vascular Health. *Obstet Gynecol Clin N Am*. 2020;47:17-28.

5. Schmella MJ, Assibey-Mensah V, Parks WT, et al. Plasma concentrations of soluble endoglin in the maternal circulation are associated with maternal vascular malperfusion lesions in the placenta of women with preeclampsia. *Placenta*. 2019;78:29-35. doi:10.1016/j.placenta.2019.02.014

6. Cui L, Shu C, Liu Z, et al. The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia. *Pregnancy Hypertens*. 2018;13:127-132. doi:10.1016/j.preghy.2018.05.011

7. Romero R, Jung E, Chaiworapongsa T, et al. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. *American Journal of Obstetrics and Gynecology*. 2022;227(4):615.e1-615.e25. doi:10.1016/j.ajog.2022.04.015

8. McBride CA, Bernstein IM, Sybenga AB, McLean KC, Orfeo T, Bravo MC. Placental Maternal Vascular Malperfusion Is Associated with Prepregnancy and Early Pregnancy Maternal Cardiovascular and Thrombotic Profiles. *Serono Sym*. 2022;3(1):50-61. doi:10.3390/reprodmed3010006

9. Demir R, Kayisli UA, Cayli S, Huppertz B. Sequential Steps During Vasculogenesis and Angiogenesis in the Very Early Human Placenta. *Placenta*. 2006;27(6-7):535-539. doi:10.1016/j.placenta.2005.05.011

10. Verma U, Verma N. *The Placenta: Development, Function, and Diseases*. (Richard Nicholson, ed.). Nova Science Publishers, Inc; 2013.

11. Parry S, Carper BA, Grobman WA, et al. Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients. *Am J Obstet Gynecol*. 2022;227(3):497.e1-497.e13. doi:10.1016/j.ajog.2022.03.064

12. Conover CA, Oxvig C. The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story. *Endocrine Reviews*. 2023;44(6):1012-1028. doi:10.1210/endrev/bnad017

13. Margioula-Siarkou G, Margioula-Siarkou C, Petousis S, et al. Soluble endoglin concentration in maternal blood as a diagnostic biomarker of preeclampsia: A systematic review and meta-analysis.

European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021;258:366-381. doi:10.1016/j.ejogrb.2021.01.039

14. Kramer AW, Lamale-Smith LM, Winn VD. Differential expression of human placental PAPP-A2 over gestation and in preeclampsia. *Placenta*. 2016;37:19-25. doi:10.1016/j.placenta.2015.11.004

15. Whorton AE, Pan AY, Palatnik A. Effects of physical activity on placental analytes in nulliparous persons. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2024;292:158-162. doi:10.1016/j.ejogrb.2023.11.018

16. Reijnders IF, Mulders AGMGJ, Windt M van der, Steegers EAP, Steegers-Theunissen RPM. The impact of periconceptional maternal lifestyle on clinical features and biomarkers of placental development and function: a systematic review. *Hum Reprod Update*. 2018;25(1):72-94. doi:10.1093/humupd/dmy037

17. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. *Circulation*. 2010;121(4):586-613. doi:10.1161/circulationaha.109.192703

18. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. *Circulation*. Published online 2022:101161CIR0000000000001078. doi:10.1161/cir.0000000000001078

19. Perak AM, Lancki N, Kuang A, et al. Associations of gestational cardiovascular health with pregnancy outcomes: the Hyperglycemia and Adverse Pregnancy Outcome study. *Am J Obstet Gynecol*. 2021;224(2):210.e1-210.e17. doi:10.1016/j.ajog.2020.07.053

20. Hardy DB, Mu X, Marchiori KS, Mottola MF. Exercise in Pregnancy Increases Placental Angiogenin without Changes in Oxidative or Endoplasmic Reticulum Stress. *Medicine & Science in Sports & Exercise*. 2021;53(9):1846-1854. doi:10.1249/MSS.0000000000002647

21. Weissgerber TL, Davies GAL, Roberts JM. Modification of angiogenic factors by regular and acute exercise during pregnancy. *Journal of Applied Physiology*. 2010;108(5):1217-1223. doi:10.1152/japplphysiol.00008.2010

22. Gilbert JS, Banek CT, Bauer AJ, Gingery A, Dreyer HC. Placental and vascular adaptations to exercise training before and during pregnancy in the rat. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 2012;303(5):R520-R526. doi:10.1152/ajpregu.00253.2012

23. Makarem N, Chau K, Miller EC, et al. Association of a Mediterranean Diet Pattern With Adverse Pregnancy Outcomes Among US Women. *JAMA Netw Open*. 2022;5(12):e2248165. doi:10.1001/jamanetworkopen.2022.48165

24. Miller C, Boushey C, Benny P, et al. Diet quality predicts hypertensive disorders of pregnancy in Asian and Pacific Islander Cohort. *Nutr Health*. Published online June 27, 2022:026010602211096. doi:10.1177/02601060221109668

25. Lu Q, Zhang X, Wang Y, et al. Sleep disturbances during pregnancy and adverse maternal and fetal outcomes: A systematic review and meta-analysis. *Sleep Medicine Reviews*. 2021;58:101436. doi:10.1016/j.smrv.2021.101436

26. Haas DM, Ehrenthal DB, Koch MA, et al. Pregnancy as a Window to Future Cardiovascular Health: Design and Implementation of the nuMoM2b Heart Health Study. *Am J Epidemiol*. 2016;183(6):519-530. doi:10.1093/aje/kwv309

27. Shephard RJ. 2011 Compendium of Physical Activities: A Second Update of Codes and MET Values. *Yearbook of Sports Medicine*. 2012;2012:126-127. doi:10.1016/j.yspm.2011.08.057

28. US Department of Health & Human Services. *Physical Activity Guidelines for Americans, 2nd Edition*. U.S. Department of Health and Human Services; 2018.

29. Block G, Coyle LM, Hartman AM, Scoppa SM. Revision of Dietary Analysis Software for the Health Habits and History Questionnaire. *American Journal of Epidemiology*. 1994;139(12):1190-1196. doi:10.1093/oxfordjournals.aje.a116965

30. Parrott MS, Bodnar LM, Simhan HN, Harger G, Markovic N, Roberts JM. Maternal cereal consumption and adequacy of micronutrient intake in the periconceptional period. *Public Health Nutrition*. 2009;12(8):1276-1283. doi:10.1017/S1368980008003881

31. Krieger N, Sidney S. Racial discrimination and blood pressure: the CARDIA Study of young black and white adults. *Am J Public Health*. 1996;86(10):1370-1378. doi:10.2105/AJPH.86.10.1370

32. Connor KM, Davidson JRT. Development of a new resilience scale: The Connor-Davidson Resilience Scale (CD-RISC). *Depression and Anxiety*. 2003;18(2):76-82. doi:10.1002/da.10113

33. Li M, Gong W, Wang S, Li Z. Trends in body mass index, overweight and obesity among adults in the USA, the NHANES from 2003 to 2018: a repeat cross-sectional survey. *BMJ Open*. 2022;12(12):e065425. doi:10.1136/bmjopen-2022-065425

34. Liu X, Chen L, Li J, et al. Physical Activity and High-Sensitivity C-Reactive Protein in Pregnancy: Does It Matter during Leisure or Work? *Medicine & Science in Sports & Exercise*. 2024;56(1):110. doi:10.1249/MSS.0000000000003287

35. Chełchowska M, Gajewska J, Mazur J, Ambroszkiewicz J, Maciejewski TM, Leibschang J. Serum pregnancy-associated plasma protein A levels in the first, second and third trimester of pregnancy: relation to newborn anthropometric parameters and maternal tobacco smoking. *Arch Med Sci*. 2016;12(6):1256-1262. doi:10.5114/aoms.2016.62908

36. Wright D, Silva M, Papadopoulos S, Wright A, Nicolaides KH. Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history. *Ultrasound in Obstetrics & Gynecology*. 2015;46(1):42-50. doi:10.1002/uog.14870

37. Uriel M, Romero Infante XC, Rincón Franco S, Ibáñez Pinilla EA, Rojas NA. Higher PAPP-A Values in Pregnant Women Complicated with Preeclampsia Than with Gestational Hypertension. *Reprod Sci*. 2023;30(8):2503-2511. doi:10.1007/s43032-023-01176-1

38. Mazidi M, Rezaie P, Kengne AP, Stathopoulou MG, Azimi-Nezhad M, Siest S. VEGF, the underlying factor for metabolic syndrome; fact or fiction? *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2017;11:S61-S64. doi:10.1016/j.dsx.2016.12.004

39. Wiewiora M, Mertas A, Gluck M, Nowowiejska-Wiewiora A, Czuba Z, Piecuch J. Effect of Weight Loss Surgery on Biomarkers of Angiogenesis in Obese Patients. *OBES SURG*. 2020;30(9):3417-3425. doi:10.1007/s11695-020-04580-7

40. Fu P, Zhu R, Jia J, et al. Aerobic exercise promotes the functions of brown adipose tissue in obese mice via a mechanism involving COX2 in the VEGF signaling pathway. *Nutr Metab (Lond)*. 2021;18(1):56. doi:10.1186/s12986-021-00581-0

41. Hoier B, Hellsten Y. Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. *Microcirculation*. 2014;21(4):301-314. doi:10.1111/micc.12117

42. Tang K, Xia FC, Wagner PD, Breen EC. Exercise-induced VEGF transcriptional activation in brain, lung and skeletal muscle. *Respiratory Physiology & Neurobiology*. 2010;170(1):16-22. doi:10.1016/j.resp.2009.10.007

43. Sirico A, Rossi ED, Degennaro VA, et al. Placental diabesity: placental VEGF and CD31 expression according to pregestational BMI and gestational weight gain in women with gestational diabetes. *Arch Gynecol Obstet*. 2023;307(6):1823-1831. doi:10.1007/s00404-022-06673-3

44. Salvolini E, Vignini A, Sabbatinelli J, et al. Nitric oxide synthase and VEGF expression in full-term placentas of obese women. *Histochem Cell Biol*. 2019;152(6):415-422. doi:10.1007/s00418-019-01819-y

45. Bhattacharjee J, Mohammad S, Goudreau AD, Adamo KB. Physical activity differentially regulates VEGF, PlGF, and their receptors in the human placenta. *Physiological Reports*. 2021;9(2):e14710. doi:10.14814/phy2.14710

46. Margioula-Siarkou G, Margioula-Siarkou C, Petousis S, et al. The role of endoglin and its soluble form in pathogenesis of preeclampsia. *Mol Cell Biochem*. 2022;477(2):479-491. doi:10.1007/s11010-021-04294-z

47. El-Dayem T, Elagwany A, Khamis M, Kamha E, Hassan A. Correlation of serum soluble endoglin to the severity of pre-eclampsia and its effect on the pregnancy outcome. *Int J Reprod Contracept Obstet Gynecol*. Published online 2016:1593-1600. doi:10.18203/2320-1770.ijrcog20161332

48. Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. *American Journal of Obstetrics and Gynecology*. 2011;204(3):244.e1-244.e12. doi:10.1016/j.ajog.2010.10.001

49. Graupner O, Verlohren S, Groten T, et al. Significance of the sFlt-1/PlGF Ratio in Certain Cohorts – What Needs to be Considered? *Geburtshilfe Frauenheilkd*. 2024;84(7):629-634. doi:10.1055/a-2320-5843

50. Beck C, Allshouse AA, Blue NR, et al. Early pregnancy BMI and angiogenesis-related biomarkers (sFlt-1/PlGF): a pathway for adverse pregnancy outcomes? *Am J Obstet Gynecol*. 2021;224(2):S662-3.

51. Zera CA, Seely EW, Wilkins-Haug LE, Lim KH, Parry SI, McElrath TF. The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies. *American Journal of Obstetrics and Gynecology*. 2014;211(3):247.e1-247.e7. doi:10.1016/j.ajog.2014.03.020

52. Aplin JD, Myers JE, Timms K, Westwood M. Tracking placental development in health and disease. *Nat Rev Endocrinol*. 2020;16(9):479-494. doi:10.1038/s41574-020-0372-6

53. Haram K, Mortensen JH, Myking O, Roald B, Magann EF, Morrison JC. Early development of the human placenta and pregnancy complications. *J Maternal-fetal Neonatal Medicine*. 2019;33(20):3538-3545. doi:10.1080/14767058.2019.1578745

54. Theilen LH, Greenland P, Varagic J, et al. Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: the nuMoM2b Heart Health Study. *Pregnancy Hypertens*. 2022;28:28-34. doi:10.1016/j.preghy.2022.01.012

55. Rolnik DL, Syngelaki A, O'Gorman N, Wright D, Nicolaides KH, Poon LC. Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy. *American Journal of Obstetrics and Gynecology*. 2024;231(3):342.e1-342.e9. doi:10.1016/j.ajog.2023.12.031

Table 1. Descriptive characteristics of participants by physical activity categories. Results presented as weighted mean ± SD or frequency (weighted percentage) as appropriate.

	High CVH (n=495)	Moderate CVH (n=916)	Poor CVH (n=220)	p-value
Maternal age (years)	28.8 ± 4.6	27.0 ± 5.8	24.9 ± 5.4	**<0.001**
BMI (kg/m^2)	23.1 ± 3.1	26.4 ± 5.6	33.8 ± 9.4	**<0.001**
Maternal race				**<0.001**
Asian	29 (4%)	23 (3%)	1 (1%)	
Black non-Hispanic	17 (4%)	119 (10%)	69 (27%)	
Hispanic	50 (10%)	182 (20%)	37 (21%)	
White non-Hispanic	378 (79%)	543 (63%)	93 (44%)	
Other	21 (3%)	49 (4%)	20 (7%)	
Educational Attainment				**<0.001**
Less than high school	9 (1%)	89 (10%)	39 (14%)	
Completed high school or GED	14 (4%)	129 (13%)	57 (34%)	
Some college	45 (10%)	190 (18%)	69 (30%)	
Associate or technical degree	38 (9%)	109 (9%)	25 (9%)	
Completed college	185 (33%)	239 (31%)	18 (9%)	
Degree work beyond college	204 (43%)	160 (19%)	12 (4%)	
Percentage of Federal Poverty Level				**<0.001**
<100%	25 (5%)	114 (15%)	48 (40%)	
100-200%	29 (8%)	115 (12%)	35 (28%)	
>200%	396 (87%)	486 (73%)	60 (32%)	
Insurance payor				**<0.001**
Commercial	331 (68%)	472 (56%)	88 (47%)	
Medicare/Medicaid	25 (5%)	272 (26%)	107 (43%)	
Military/Other	2 (1%)	14 (1%)	3 (<1%)	
Two or more sources	125 (23%)	137 (16%)	11 (7%)	
None (personal income)	11 (3%)	10 (1%)	6 (3%)	
Perceived racial discrimination				**0.001**
None	398 (81%)	665 (74%)	148 (68%)	
Moderate	67 (14%)	180 (19%)	46 (18%)	
High	30 (5%)	71 (7%)	26 (14%)	
Resilience	82.5 ± 10.1	78.4 ± 12.3	77.5 ± 11.6	**<0.001**
Composite CVH score	87.3 ± 5.3	66.3 ± 8.3	42.5 ± 6.6	**<0.001**
APO	268 (13%)	553 (16%)	164 (27%)	**<0.001**

High cardiovascular health (CVH): 80-100 points; Moderate CVH: 50-79 points; Poor CVH: <50 points. Significance accepted at p<0.01. Perceived racial discrimination scores from Krieger discrimination scale: None: 0; Moderate: 1-2; High: 3+. Resilience scores on a scale from 0-100. APO: adverse pregnancy outcome; BMI: body mass index; GED: general education diploma.

Table 2. Association between 1st trimester cardiovascular health score categories and placental biomarkers in the 1st and 2nd trimesters.

	CVH Category	ß coefficient (95% CI) Model 1	p-value	ß coefficient (95% CI) Model 2	p-value
First trimester biomarkers					
PAPP-A	High	Reference		Reference	
(log mU/mL)	Moderate	-0.066 (-0.130, -0.001)	0.046	**-0.108 (-0.182, -0.034)**	**0.004**
	Poor	**-0.217 (-0.322, -0.113)**	**<0.001**	**-0.376 (-0.509, -0.243)**	**<0.001**
VEGF	High	Reference		Reference	
(log pg/mL)	Moderate	0.029 (-0.028, 0.086)	0.314	0.024 (-0.042, 0.091)	0.474
	Poor	**0.153 (0.039, 0.268)**	**0.009**	**0.224 (0.065, 0.383)**	**0.006**
PlGF	High	Reference		Reference	
(log pg/mL)	Moderate	0.017 (-0.021, 0.054)	0.385	-0.002 (-0.046, 0.042)	0.926
	Poor	0.016 (-0.044, 0.076)	0.599	-0.050 (-0.131, 0.031)	0.224
sFlt-1	High	Reference		Reference	
(log pg/mL)	Moderate	-0.012 (-0.039, 0.015)	0.374	-0.014 (-0.043, 0.015)	0.343
	Poor	-0.041 (-0.080, -0.002)	0.041	**-0.068 (-0.115, -0.022)**	**0.004**
sEng	High	Reference		Reference	
(ng/mL)	Moderate	**-0.387 (-0.610, -0.164)**	**0.001**	-0.304 (-0.548, -0.060)	0.015
	Poor	**-1.109 (-1.429, -0.788)**	**<0.001**	**-1.014 (-1.432, -0.596)**	**<0.001**
Second trimester biomarkers					
PAPP-A	High	Reference		Reference	
(log mU/mL)	Moderate	0.014 (-0.020, 0.048)	0.422	-0.010 (-0.048, 0.028)	0.603
	Poor	-0.040 (-0.097, 0.017)	0.169	**-0.117 (-0.192, -0.042)**	**0.002**
VEGF	High	Reference		Reference	
(log pg/mL)	Moderate	0.001 (-0.043, 0.045)	0.962	0.009 (-0.040, 0.057)	0.729
	Poor	0.051 (-0.021, 0.123)	0.166	0.038 (-0.050, 0.126)	0.399
PlGF	High	Reference		Reference	
(log pg/mL)	Moderate	-0.007 (-0.049, 0.035)	0.740	-0.013 (-0.061, 0.036)	0.608
	Poor	-0.021 (-0.076, 0.034)	0.462	-0.053 (-0.118, 0.013)	0.114
sFlt-1	High	Reference		Reference	
(log pg/mL)	Moderate	0.014 (-0.004, 0.032)	0.135	0.015 (-0.005, 0.035)	0.132
	Poor	0.032 (0.002, 0.062)	0.038	0.018 (-0.018, 0.054)	0.325
sEng	High	Reference		Reference	
(ng/mL)	Moderate	0.051 (-0.080, 0.181)	0.445	0.015 (-0.122, 0.152)	0.825
	Poor	-0.055 (-0.241, 0.131)	0.562	-0.221 (-0.480, 0.038)	0.094

High cardiovascular health (CVH): 80-100 points; Moderate CVH: 50-79 points; Poor CVH: <50 points. Model 1 is adjusted for gestational age at the blood draw (1st and 2nd trimester analyses) and 1st trimester biomarker concentration (2nd trimester analyses only). Model 2 is additionally adjusted for maternal age, race, educational attainment, income, insurance payor, perceived racial discrimination, and resilience in a backwards stepwise approach. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

Table 3. Association between 1st trimester component scores and placental biomarkers in the 1st and 2nd trimesters. ß coefficients are per 10-point increase in component score. A higher score is healthier.

	ß coefficient per 10-point increase in CVH score (95% CI) Model 1	p-value	ß coefficient per 10-point increase in CVH score (95% CI) Model 2	p-value
First trimester biomarkers				
Log PAPP-A (mU/mL)				
Body Mass Index	**0.046 (0.038, 0.054)**	**<0.001**	**0.056 (0.046, 0.066)**	**<0.001**
Blood Pressure	**0.050 (0.032, 0.065)**	**<0.001**	0.022 (0.002, 0.043)	0.033
Smoking	-0.0002 (-0.008, 0.008)	0.956	-0.0002 (-0.010, 0.009)	0.964
Diet	-0.003 (-0.011, 0.006)	0.561	-0.004 (-0.015, 0.008)	0.506
Sleep	0.002 (-0.012, 0.016)	0.788	0.005 (-0.011, 0.021)	0.559
Log VEGF (pg/mL)				
Body Mass Index	**-0.040 (-0.050, -0.031)**	**<0.001**	**-0.044 (-0.054, -0.033)**	**<0.001**
Blood Pressure	**-0.035 (-0.050, -0.020)**	**<0.001**	-0.011 (-0.027, 0.006)	0.196
Smoking	-0.004 (-0.011, 0.003)	0.280	0.002 (-0.006, 0.009)	0.668
Diet	-0.0003 (-0.008, 0.008)	0.933	0.008 (-0.002, 0.017)	0.118
Sleep	-0.003 (-0.016, 0.009)	0.597	-0.007 (-0.022, 0.008)	0.341
Log PlGF (pg/mL)				
Body Mass Index	0.002 (-0.002, 0.006)	0.281	0.003 (-0.002, 0.008)	0.262
Blood Pressure	0.006 (-0.001, 0.012)	0.072	0.006 (-0.001, 0.013)	0.094
Smoking	**-0.006 (-0.010, -0.002)**	**0.004**	-0.006 (-0.010, -0.0001)	0.018
Diet	-0.005 (-0.009, -0.0001)	0.046	0.001 (-0.005, 0.007)	0.772
Sleep	-0.002 (-0.008, 0.004)	0.559	0.004 (-0.003, 0.011)	0.317
Log sFlt-1 (pg/mL)				
Body Mass Index	**0.014 (0.010, 0.017)**	**<0.001**	**0.015 (0.011, 0.019)**	**<0.001**
Blood Pressure	**0.012 (0.006, 0.017)**	**<0.001**	0.002 (-0.005, 0.008)	0.592
Smoking	0.001 (-0.002, 0.004)	0.392	-0.0004 (-0.004, 0.003)	0.837
Diet	-0.001 (-0.004, 0.003)	0.729	-0.003 (-0.007, 0.001)	0.188
Sleep	-0.002 (-0.007, 0.004)	0.506	0.001 (-0.006, 0.009)	0.691
sEng (ng/mL)				
Body Mass Index	**0.166 (0.142, 0.190)**	**<0.001**	**0.164 (0.137, 0.192)**	**<0.001**
Blood Pressure	**0.113 (0.070, 0.156)**	**<0.001**	-0.031 (-0.079, 0.018)	0.212
Smoking	**0.050 (0.024, 0.076)**	**<0.001**	0.035 (0.008, 0.062)	0.011
Diet	0.034 (0.004, 0.063)	0.026	0.014 (-0.019 0.046)	0.416
Sleep	**0.064 (0.020, 0.11)**	**0.004**	0.046 (-0.005, 0.097)	0.075
Second trimester biomarkers				
Log PAPP-A (mU/mL)				
Body Mass Index	**0.017 (0.011, 0.023)**	**<0.001**	**0.024 (0.018, 0.031)**	**<0.001**
Blood Pressure	0.010 (0.001, 0.018)	0.023	0.001 (-0.008, 0.010_	0.846
Smoking	0.005 (0.0001, 0.009)	0.044	0.004 (-0.001, 0.009)	0.088
Diet	-0.003 (-0.008, 0.002)	0.284	-0.002 (-0.007, 0.004)	0.561
Sleep	-0.005 (-0.012, 0.003)	0.243	-0.004 (-0.013, 0.006)	0.442

Log VEGF (pg/mL)				
Body Mass Index	-0.004 (-0.010, 0.001)	0.117	-0.006 (-0.013, 0.0002)	0.059
Blood Pressure	-0.004 (-0.012, 0.005)	0.412	-0.003 (-0.014, 0.007)	0.525
Smoking	-0.0004 (-0.006, 0.005)	0.877	0.0006 (-0.006, 0.007)	0.849
Diet	-0.002 (-0.008, 0.004)	0.556	-0.0001 (-0.007, 0.007)	0.975
Sleep	0.002 (-0.007, 0.011)	0.691	0.006 (-0.006, 0.017)	0.351
Log PlGF (pg/mL)				
Body Mass Index	**0.013 (0.009, 0.017)**	**<0.001**	**0.013 (0.008, 0.018)**	**<0.001**
Blood Pressure	0.012 (0.002, 0.023)	0.025	0.005 (-0.008, 0.017)	0.492
Smoking	0.0004 (-0.004, 0.005)	0.858	0.003 (-0.003, 0.009)	0.323
Diet	0.0007 (-0.006, 0.007)	0.828	-0.002 (-0.001, 0.007)	0.732
Sleep	-0.003 (-0.009, 0.004)	0.427	-0.0001 (-0.008, 0.007)	0.983
Log sFlt-1 (pg/mL)				
Body Mass Index	0.0001 (-0.003, 0.003)	0.953	0.001 (-0.002, 0.004)	0.431
Blood Pressure	-0.004 (-0.008, 0.0002)	0.065	-0.001 (-0.005, 0.003)	0.746
Smoking	0.0002 (-0.002, 0.003)	0.860	0.001 (-0.002, 0.004)	0.430
Diet	-0.001 (-0.004, 0.001)	0.347	0.0003 (-0.003, 0.004)	0.849
Sleep	-0.0004 (-0.004, 0.004)	0.853	-0.001 (-0.006, 0.004)	0.823
sEng (ng/mL)				
Body Mass Index	0.004 (-0.011, 0.020)	0.582	0.006 (-0.013, 0.025)	0.515
Blood Pressure	-0.011 (-0.037, 0.014)	0.377	-0.012 (-0.044, 0.019)	0.442
Smoking	-0.007 (-0.022, 0.008)	0.362	0.005 (-0.013, 0.023)	0.590
Diet	-0.004 (-0.022, 0.014)	0.658	-0.001 (-0.025, 0.023)	0.917
Sleep	-0.011 (-0.039, 0.017)	0.441	-0.007 (-0.038, 0.024)	0.659

Model 1 is adjusted for gestational age at the blood draw (1st and 2nd trimester analyses) and 1st trimester biomarker concentration (2nd trimester analyses only). Model 2 is additionally adjusted for maternal age, race, body mass index, educational attainment, income, insurance payor, perceived racial discrimination, and resilience in a backwards stepwise approach. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

Figure 1. CONSORT diagram of included and excluded participants. nuMoM2b: Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be; GA: gestational age; SGA: small for gestational age; PTB: preterm (<37 weeks GA) birth.

Figure 2. Differences between physical activity categories, defined as: None = 0 minutes/week; Insufficient = 1-149 minutes per week; Sufficient = 150-299 minutes/week; High = ≥300 minutes/week. *Indicates p<0.01 **(a)** Any 1st trimester physical activity associated with lower 2nd trimester PAPP-A than none; **(b)** Significantly lower weighted rate of APO in those with sufficient weekly physical activity compared to none; **(c)** No weekly 1st trimester physical activity associated with lower 1st trimester VEGF than those with insufficient or high weekly physical activity (p<0.001), while those with sufficient weekly physical activity were non-significantly lower (p=0.02); **(d)** High weekly 1st trimester physical activity associated with lower 1st trimester sFlt-1 than no weekly physical activity. PAPP-A: pregnancy-associated plasma protein A; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor. Data presented as weighted means with 95% confidence intervals **(a, c, d)** or weighted percentages **(b)**.

Figure 3. Associations of composite cardiovascular health (CVH), BMI, and physical activity components with circulating placental biomarker concentrations in the 1st and 2nd trimesters. Hypothesis: healthier CVH and components are associated with higher PAPP-A, VEGF, and PlGF, and with lower sEng and sFlt-1. PAPP-A: pregnancy-associated plasma protein A; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

Supplemental Tables

Table S1. Cardiovascular Health Scoring algorithm for health behaviors in pregnancy. HEI: Healthy Eating Index.

	Value	Cardiovascular Health Score
Physical Activity (minutes moderate-to-vigorous physical activity/week)	0	0
	1-29	20
	30-59	40
	60-89	60
	90-119	80
	120-149	90
	150+	100
Diet (HEI percentile)	<25th	0
	25th-49th	25
	50th-74th	50
	75th-94th	80
	$\geq$95th	100
Sleep Duration (mean hours/night)	<4	0
	4 - <5	20
	5 - <6 or $\geq$10	40
	6 - <7	70
	9 - <10	90
	7 - <9	100
Smoking	Current smoking	0
	Smoked within 3 months of conception	25
	Former smoker, quit prior to 3 months before conception	50
	Never smoker	100
	Lives with current smoker	Subtract 20 points unless score already = 0

Table S2. Covariates included in each model following backwards stepwise selection (p to remain <0.2).

	Cross-sectional analysis	Longitudinal analysis
PAPP-A		
Composite CVH Score	Age, education, race/ethnicity, insurance	Age, discrimination, income, race/ethnicity
BMI	Age, education, insurance, race/ethnicity	Race/ethnicity, income, resilience
Blood Pressure	Age, BMI, race/ethnicity, insurance	Race/ethnicity, BMI, income
Physical Activity	Age, BMI, discrimination, race/ethnicity, insurance	Race/ethnicity, BMI, income
Smoking	Age, BMI, education, race/ethnicity, insurance	Age, BMI, education, income, race/ethnicity
Diet	Age, BMI, education, race/ethnicity, insurance	Race/ethnicity, BMI, discrimination, income
Sleep	Age, BMI, education, race/ethnicity, insurance	Race/ethnicity, BMI, discrimination, income
VEGF		
Composite CVH Score	Education	Race/ethnicity
BMI	Age, income	Race/ethnicity
Blood Pressure	Age, BMI, income	Race/ethnicity, BMI
Physical Activity	Age, BMI	Race/ethnicity, BMI
Smoking	Age, BMI, income	Race/ethnicity, BMI
Diet	Age, BMI, income	Race/ethnicity, BMI, discrimination
Sleep	Age, BMI, income	Race/ethnicity, BMI
PlGF		
Composite CVH Score	Discrimination, education, income, race/ethnicity	Race/ethnicity
BMI	Race/ethnicity	Age, race/ethnicity
Blood Pressure	Race/ethnicity	Age, BMI, education, race/ethnicity
Physical Activity	Race/ethnicity, BMI, education	Age, BMI, race/ethnicity
Smoking	Race/ethnicity, BMI	Age, BMI, education, race/ethnicity
Diet	Discrimination, BMI, education, income, race/ethnicity	Age, BMI, race/ethnicity
Sleep	Discrimination, BMI, education, income, race/ethnicity	Age, BMI, race/ethnicity
sFlt-1		
Composite CVH Score	Education, race/ethnicity, discrimination	Race/ethnicity
BMI	Insurance, race/ethnicity	Age, race/ethnicity, education, discrimination
Blood Pressure	Insurance, BMI, race/ethnicity	Race/ethnicity, education
Physical Activity	Insurance, BMI, race/ethnicity	Race/ethnicity, education
Smoking	Insurance, BMI, race/ethnicity	Race/ethnicity, education
Diet	Race/ethnicity, BMI	Race/ethnicity, education
Sleep	Insurance, BMI, race/ethnicity	Education
sEng		

Composite CVH Score	Age, income	Age, education, race/ethnicity, discrimination
BMI	Discrimination	Age, education, race/ethnicity, discrimination
Blood Pressure	Discrimination, BMI, resilience	Age, BMI, education, race/ethnicity, discrimination
Physical Activity	Discrimination, BMI, resilience, race/ethnicity	Age, BMI, education, race/ethnicity, discrimination
Smoking	Discrimination, BMI	Age, BMI, education, race/ethnicity, discrimination
Diet	Race/ethnicity, BMI	Age, BMI, education, race/ethnicity, discrimination
Sleep	Discrimination, BMI, race/ethnicity	Age, BMI, education, race/ethnicity, discrimination

BMI: body mass index; PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.

Table S3. Descriptive characteristics of full versus selected sample. Data presented as mean $\pm$ SD or frequency (%). Means, SD, and percentages for the selected sample are weighted by sampling proportion. Hypothesis tests were conducted using t-tests or Chi-square tests, as appropriate. Significance accepted at p<0.05.

	Full sample (N=10,038)	Selected sample (n=2,188)	p-value
Maternal age (years)	26.9 $\pm$ 5.67	26.9 $\pm$ 5.65	0.88
BMI (kg/m^2)	26.3 $\pm$ 6.33	26.0 $\pm$ 6.10	**0.02**
Maternal race			**0.01**
Asian	407 (4%)	73 (3%)	
Black non-Hispanic	1418 (14%)	352 (13%)	
Hispanic	1700 (17%)	360 (16%)	
White non-Hispanic	5989 (60%)	1277 (63%)	
Other	514 (5%)	125 (5%)	
Educational Attainment			0.81
Less than high school	816 (8%)	218 (8%)	
Completed high school or GED	1171 (12%)	289 (12%)	
Some college	1948 (19%)	446 (19%)	
Associate or technical degree	1005 (10%)	233 (10%)	
Completed college	2772 (28%)	541 (27%)	
Degree work beyond college	2308 (23%)	460 (24%)	
Percentage of Federal Poverty Level			0.17
<100%	1297 (16%)	298 (15%)	
100-200%	1169 (14%)	255 (13%)	
>200%	5662 (70%)	1164 (72%)	
Insurance payor			**0.001**
Commercial	5239 (53%)	1128 (56%)	
Medicare/Medicaid	2711 (27%)	619 (24%)	
Military/Other	164 (2%)	31 (1%)	
Two or more sources	1576 (16%)	337 (17%)	
None (personal income)	269 (3%)	48 (2%)	
Perceived racial discrimination			**<0.001**
None	7172 (71%)	1621 (76%)	
Moderate	1587 (16%)	397 (17%)	
High	1279 (13%)	170 (7%)	
Resilience	79.3 $\pm$ 11.74	79.7 $\pm$ 11.84	0.16
APO	1502 (15%)	1349 (16%)	0.27

APO: adverse pregnancy outcome; BMI: body mass index; GED: general education diploma.

Table S4. Weighted absolute placental biomarker concentrations in each trimester by cardiovascular health categories. Data presented as weighted median and interquartile range.

	High CVH (n=495)	Moderate CVH (n=916)	Poor CVH (n=220)	p-value
First trimester biomarker concentrations				
PAPP-A (mU/mL)	1156.4	975.0	650.9	0.038
	(565.7 – 2004.0)	(466.2 – 1972.4)	(322.1 – 1598.8)	
VEGF (pg/mL)	0.72	0.74	0.85	0.777
	(0.50 – 1.05)	(0.52 – 1.15)	(0.56 – 1.62)	
PlGF (pg/mL)	44.5	41.2	43.3	0.193
	(29.5 – 59.3)	(29.9 – 58.9)	(29.4 – 60.0)	
sFlt-1 (pg/mL)	970.5	901.9	841.8	0.028
	(711.2 – 1215.4)	(704.4 – 1182.9)	(643.8 – 1071.1)	
sEng (ng/mL)	6.77	6.27	5.43	**<0.001**
	(5.77 – 7.83)	(5.42 – 7.33)	(4.77 – 6.69)	
Second trimester biomarker concentrations				
PAPP-A (mU/mL)	9662.3	8867.7	7487.5	**<0.001**
	(5645.7 – 15111.4)	(5369.1 – 14644.7)	(3436.1 – 11521.9)	
VEGF (pg/mL)	0.92	0.95	1.08	0.112
	(0.63 – 1.53)	(0.66 – 1.51)	(0.72 – 1.97)	
PlGF (pg/mL)	203.1	185.4	187.9	0.960
	(139.8 – 283.5)	(132.2 – 282.1)	(121.9 – 302.6)	
sFlt-1 (pg/mL)	866.9	865.5	857.1	0.671
	(624.9 – 1169.7)	(645.6 – 1215.7)	(648.4 – 1147.2)	
sEng (ng/mL)	5.57	5.29	4.96	**<0.001**
	(4.89 – 6.36)	(4.62 – 6.16)	(4.02 – 5.75)	

PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor

Table S5. Adjusted marginal means (95% confidence intervals) between physical activity categories and 1st and 2nd trimester placental analytes.

	Adjusted Marginal Mean (95% CI) Model 1	p-value	Adjusted Marginal Mean (95% CI) Model 2	p-value
First trimester biomarkers				
Log PAPP-A (mU/mL)				
None	2.91 (2.87, 2.96)	Reference	2.92 (2.86, 2.97)	Reference
Insufficient	2.92 (2.88, 2.96)	0.822	2.93 (2.88, 2.97)	0.813
Sufficient	2.96 (2.91, 3.01)	0.177	2.93 (2.88, 2.99)	0.727
High	2.84 (2.77, 2.92)	0.130	2.81 (2.72, 2.89)	0.040
Log VEGF (pg/mL)				
None	-0.14 (-0.18, -0.10)	Reference	-0.19 (-0.23, -0.14)	Reference
Insufficient	-0.09 (-0.14, -0.05)	0.115	**-0.08 (-0.13, -0.03)**	**0.002**
Sufficient	-0.13 (-0.18, -0.08)	0.731	-0.11 (-0.16, -0.06)	0.039
High	-0.06 (-0.12, 0.002)	0.041	**-0.06 (-0.12, 0.01)**	**0.002**
Log PlGF (pg/mL)				
None	1.60 (1.58, 1.63)	Reference	1.58 (1.54, 1.61)	Reference
Insufficient	1.61 (1.59, 1.64)	0.580	1.61 (1.58, 1.64)	0.157
Sufficient	1.61 (1.58, 1.64)	0.649	1.61 (1.57, 1.65)	0.220
High	1.60 (1.57, 1.63)	0.982	1.61 (1.58, 1.64)	0.219
Log sFlt-1 (pg/mL)				
None	2.96 (2.94, 2.98)	Reference	2.98 (2.96, 3.00)	Reference
Insufficient	2.97 (2.95, 2.99)	0.478	2.97 (2.95, 2.99)	0.669
Sufficient	2.97 (2.95, 3.00)	0.475	2.97 (2.95, 3.00)	0.706
High	2.94 (2.91, 2.96)	0.117	**2.92 (2.90, 2.95)**	**0.003**
sEng (ng/mL)				
None	6.45 (6.28, 6.62)	Reference	6.60 (6.40, 6.79)	Reference
Insufficient	6.60 (6.43, 6.78)	0.225	6.65 (6.48, 6.82)	0.655
Sufficient	6.59 (6.38, 6.79)	0.322	6.48 (6.27, 6.70)	0.438
High	6.61 (6.39, 6.83)	0.251	6.58 (6.35, 6.80)	0.904
Second trimester biomarkers				
Log PAPP-A (mU/mL)				
None	3.98 (3.95, 4.00)	Reference	3.98 (3.95, 4.01)	Reference
Insufficient	**3.92 (3.90, 3.95)**	**0.005**	**3.92 (3.89, 3.94)**	**0.003**
Sufficient	3.93 (3.89, 3.96)	0.022	**3.92 (3.89, 3.95)**	**0.006**
High	3.94 (3.91, 3.97)	0.081	**3.91 (3.88, 3.95)**	**0.008**
Log VEGF (pg/mL)				
None	0.02 (-0.01, 0.05)	Reference	0.009 (-0.029, 0.048)	Reference
Insufficient	0.02 (-0.01, 0.05)	0.982	0.01 (-0.02, 0.05)	0.879
Sufficient	0.04 (0.004, 0.081)	0.403	0.044 (-0.001, 0.089)	0.253
High	0.02 (-0.02, 0.06)	0.858	0.02 (-0.03, 0.06)	0.813
Log PlGF (pg/mL)				

None	2.27 (2.23, 2.30)	Reference	2.28 (2.24, 2.32)	Reference
Insufficient	2.25 (2.22, 2.28)	0.558	2.24 (2.21, 2.71)	0.159
Sufficient	2.27 (2.23, 2.31)	0.856	2.25 (2.20, 2.30)	0.454
High	2.26 (2.22, 2.30)	0.783	2.23 (2.18, 2.27)	0.129
Log sFlt-1 (pg/mL)				
None	2.96 (2.95, 2.97)	Reference	2.97 (2.95, 2.98)	Reference
Insufficient	2.94 (2.92, 2.95)	0.031	2.94 (2.92, 2.95)	0.011
Sufficient	2.94 (2.93, 2.96)	0.092	2.95 (2.93, 2.97)	0.216
High	2.95 (2.93, 2.97)	0.533	2.95 (2.93, 2.97)	0.258
sEng (ng/mL)				
None	5.51 (5.42, 5.60)	Reference	5.57 (5.46, 5.68)	Reference
Insufficient	5.62 (5.52, 5.73)	0.100	5.67 (5.56, 5.79)	0.215
Sufficient	5.55 (5.44, 5.66)	0.585	5.59 (5.46, 5.71)	0.855
High	5.58 (5.46, 5.70)	0.351	5.57 (5.45, 5.69)	0.996

Physical activity categories defined as: None = 0 minutes/week; Insufficient = 1-149 minutes/week; Sufficient = 150-299 minutes/week; High = ≥300 minutes per week. Model 1 adjusted for gestational age at blood draw and 1st trimester analyte concentration. Model 2 additionally adjusted for maternal age, race, body mass index, educational attainment, income, insurance payor, perceived racial discrimination, and resilience in a backwards stepwise approach. PAPP-A: pregnancy-associated plasma protein A; PlGF: placental growth factor; sEng: soluble endoglin; sFlt-1: soluble FMS-like tyrosine kinase 1; VEGF: vascular endothelial growth factor.